Penumbra, Inc. (PEN): Price and Financial Metrics
PEN Price/Volume Stats
Current price | $234.36 | 52-week high | $348.67 |
Prev. close | $222.15 | 52-week low | $180.93 |
Day low | $222.60 | Volume | 360,700 |
Day high | $235.56 | Avg. volume | 343,040 |
50-day MA | $251.09 | Dividend yield | N/A |
200-day MA | $258.02 | Market Cap | 9.07B |
PEN Stock Price Chart Interactive Chart >
PEN POWR Grades
- Growth is the dimension where PEN ranks best; there it ranks ahead of 99.9% of US stocks.
- The strongest trend for PEN is in Quality, which has been heading up over the past 26 weeks.
- PEN ranks lowest in Momentum; there it ranks in the 4th percentile.
PEN Stock Summary
- With a price/earnings ratio of 220.19, PENUMBRA INC P/E ratio is greater than that of about 97.51% of stocks in our set with positive earnings.
- The price/operating cash flow metric for PENUMBRA INC is higher than 97.99% of stocks in our set with a positive cash flow.
- In terms of twelve month growth in earnings before interest and taxes, PENUMBRA INC is reporting a growth rate of -210.06%; that's higher than merely 6.23% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to PENUMBRA INC are HLLY, PUBM, SONM, CRSR, and LZ.
- PEN's SEC filings can be seen here. And to visit PENUMBRA INC's official web site, go to www.penumbrainc.com.
PEN Valuation Summary
- PEN's price/sales ratio is 9.8; this is 133.33% higher than that of the median Healthcare stock.
- PEN's price/sales ratio has moved up 1.5 over the prior 101 months.
Below are key valuation metrics over time for PEN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
PEN | 2023-12-29 | 9.8 | 8.8 | 239.0 | 203.0 |
PEN | 2023-12-28 | 9.9 | 8.9 | 242.8 | 206.1 |
PEN | 2023-12-27 | 10.1 | 9.1 | 247.3 | 209.9 |
PEN | 2023-12-26 | 10.1 | 9.1 | 247.2 | 209.8 |
PEN | 2023-12-22 | 10.0 | 9.0 | 245.7 | 208.6 |
PEN | 2023-12-21 | 10.0 | 9.0 | 245.7 | 208.6 |
PEN Growth Metrics
- The 4 year revenue growth rate now stands at 99.67%.
- Its 4 year price growth rate is now at 120.95%.
- Its year over year cash and equivalents growth rate is now at 22.52%.
The table below shows PEN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 847.133 | -55.661 | -2.002 |
2022-09-30 | 829.928 | -66.268 | -30.512 |
2022-06-30 | 806.367 | -16.909 | -19.391 |
2022-03-31 | 782.281 | 19.356 | -6.473 |
2021-12-31 | 747.59 | 9.502 | 5.284 |
2021-09-30 | 710.477 | 16.689 | 33.565 |
PEN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PEN has a Quality Grade of C, ranking ahead of 49.95% of graded US stocks.
- PEN's asset turnover comes in at 0.794 -- ranking 38th of 186 Medical Equipment stocks.
- IVC, NTUS, and MLSS are the stocks whose asset turnover ratios are most correlated with PEN.
The table below shows PEN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.794 | 0.618 | 0.009 |
2021-03-31 | 0.728 | 0.610 | -0.030 |
2020-12-31 | 0.728 | 0.603 | -0.054 |
2020-09-30 | 0.738 | 0.635 | -0.038 |
2020-06-30 | 0.774 | 0.658 | 0.017 |
2020-03-31 | 0.880 | 0.676 | 0.079 |
PEN Price Target
For more insight on analysts targets of PEN, see our PEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $319.80 | Average Broker Recommendation | 1.31 (Strong Buy) |
Penumbra, Inc. (PEN) Company Bio
Penumbra Inc. is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. The company was founded in 2004 and is based in Alameda, CA.
Latest PEN News From Around the Web
Below are the latest news stories about PENUMBRA INC that investors may wish to consider to help them evaluate PEN as an investment opportunity.
5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024. |
Penumbra (PEN) Stock Up 16.2% YTD: Will the Rally Continue?Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance. |
Is Penumbra (PEN) a Good Short Position?Diamond Hill Capital, an investment management company, released its “Long-Short Fund” third-quarter 2023 investor letter. A copy of the same can be downloaded here. The positive returns of the portfolio outperformed the Russell 1000 Index and the blended benchmark (60% Russell 1000 Index/40% Bloomberg US Treasury Bills 1-3 Month Index), both of which were negative in […] |
Here's Why You Should Invest in Penumbra (PEN) Stock NowInvestors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses. |
Penumbra, Inc. to Present at the J.P. Morgan 42nd Annual Healthcare ConferencePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on Monday, January 8, 2024. |
PEN Price Returns
1-mo | -13.38% |
3-mo | -7.03% |
6-mo | -10.70% |
1-year | -10.89% |
3-year | -12.15% |
5-year | 48.56% |
YTD | -6.83% |
2023 | 13.07% |
2022 | -22.57% |
2021 | 64.18% |
2020 | 6.53% |
2019 | 34.43% |
Continue Researching PEN
Here are a few links from around the web to help you further your research on Penumbra Inc's stock as an investment opportunity:Penumbra Inc (PEN) Stock Price | Nasdaq
Penumbra Inc (PEN) Stock Quote, History and News - Yahoo Finance
Penumbra Inc (PEN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...